SeaSpine Stock Forecast, Price & News

+0.45 (+2.35 %)
(As of 07/30/2021 12:00 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume109,935 shs
Average Volume155,905 shs
Market Capitalization$649.60 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive SPNE News and Ratings via Email

Sign-up to receive the latest news and ratings for SeaSpine and its competitors with MarketBeat's FREE daily newsletter.

SeaSpine logo

About SeaSpine

SeaSpine Holdings Corporation, a medical technology company, focuses on the design, development, and commercialization of surgical solutions for the treatment of spinal disorders in the United States and internationally. The company provides orthobiologics and spinal implant solutions for the neurosurgeons and orthopedic spine surgeons to perform fusion procedures in the lumbar, thoracic, and cervical spine. Its orthobiologics products include demineralized bone matrices (DBM), collagen ceramic matrices, demineralized cancellous allograft bone products, and synthetic bone void fillers to improve bone fusion rates in a range of orthopedic surgeries, including spine, hip, and extremities procedures. The company also offers orthobiologics products in various forms, such as fibers, putties, pastes, strips, and demineralized bone matrices. Its spinal implant portfolio comprises products for spinal decompression, alignment, and stabilization that are used to facilitate fusion in degenerative, minimally invasive surgery, and complex spinal deformity procedures throughout the lumbar, thoracic, and cervical spine. The company has development and licensing agreement with restor3d, Inc. and 7D Surgical, Inc. to develop 3D-printed interbody devices. SeaSpine Holdings Corporation was incorporated in 2015 and is headquartered in Carlsbad, California.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

2.42 out of 5 stars

Analyst Opinion: 3.5Community Rank: 4.7Dividend Strength: 0.0Insider Behavior: 3.3Valuation: 0.6 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

SeaSpine (NASDAQ:SPNE) Frequently Asked Questions

Is SeaSpine a buy right now?

5 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for SeaSpine in the last year. There are currently 5 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" SeaSpine stock.
View analyst ratings for SeaSpine
or view top-rated stocks.

What stocks does MarketBeat like better than SeaSpine?

Wall Street analysts have given SeaSpine a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but SeaSpine wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting SeaSpine?

SeaSpine saw a increase in short interest during the month of July. As of July 15th, there was short interest totaling 574,500 shares, an increase of 29.1% from the June 30th total of 444,900 shares. Based on an average daily trading volume, of 175,500 shares, the days-to-cover ratio is currently 3.3 days. Currently, 1.8% of the shares of the stock are sold short.
View SeaSpine's Short Interest

When is SeaSpine's next earnings date?

SeaSpine is scheduled to release its next quarterly earnings announcement on Monday, August 2nd 2021.
View our earnings forecast for SeaSpine

How can I listen to SeaSpine's earnings call?

SeaSpine will be holding an earnings conference call on Monday, August 2nd at 5:00 PM Eastern. Interested parties can register for or listen to the call using this link.

How were SeaSpine's earnings last quarter?

SeaSpine Holdings Co. (NASDAQ:SPNE) released its quarterly earnings results on Sunday, May, 2nd. The medical equipment provider reported ($0.46) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.30) by $0.16. The medical equipment provider had revenue of $41.95 million for the quarter, compared to analysts' expectations of $41.75 million. SeaSpine had a negative net margin of 27.06% and a negative trailing twelve-month return on equity of 25.16%.
View SeaSpine's earnings history

How has SeaSpine's stock been impacted by COVID-19 (Coronavirus)?

SeaSpine's stock was trading at $10.73 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, SPNE shares have increased by 82.6% and is now trading at $19.59.
View which stocks have been most impacted by COVID-19

What guidance has SeaSpine issued on next quarter's earnings?

SeaSpine issued an update on its FY 2021 earnings guidance on Tuesday, May, 11th. The company provided earnings per share (EPS) guidance of - for the period. The company issued revenue guidance of $193 million-$198 million, compared to the consensus revenue estimate of $191.31 million.

What price target have analysts set for SPNE?

5 Wall Street analysts have issued twelve-month price objectives for SeaSpine's stock. Their forecasts range from $22.00 to $30.00. On average, they anticipate SeaSpine's stock price to reach $25.20 in the next twelve months. This suggests a possible upside of 28.6% from the stock's current price.
View analysts' price targets for SeaSpine
or view top-rated stocks among Wall Street analysts.

Who are SeaSpine's key executives?

SeaSpine's management team includes the following people:
  • Mr. Keith C. Valentine, Pres, CEO & Director (Age 53, Pay $977.29k)
  • Mr. John J. Bostjancic, Sr. VP, CFO & Treasurer (Age 50, Pay $556.62k)
  • Mr. Patrick L. Keran, Sr. VP, Gen. Counsel & Sec. (Age 49, Pay $549.42k)
  • Carrie Mendivil, Head of Investor Relations
  • Mr. John J. Winge, VP of Sales (Age 54)
  • Mr. Tyler P. Lipschultz, Sr. VP of Orthobiologics & Bus. Devel. (Age 54)
  • Mr. Dennis L. Cirino, Sr. VP of Global Spinal Systems (Age 51)
  • Paul Benny, VP, Corp. Controller, Assistant Treasurer & Assistant Sec.

What is Keith Valentine's approval rating as SeaSpine's CEO?

23 employees have rated SeaSpine CEO Keith Valentine on Keith Valentine has an approval rating of 79% among SeaSpine's employees.

Who are some of SeaSpine's key competitors?

What other stocks do shareholders of SeaSpine own?

Based on aggregate information from My MarketBeat watchlists, some companies that other SeaSpine investors own include AbbVie (ABBV), Corbus Pharmaceuticals (CRBP), Gilead Sciences (GILD), Kura Oncology (KURA), Recro Pharma (REPH), Rigel Pharmaceuticals (RIGL), Spectrum Pharmaceuticals (SPPI), ViewRay (VRAY), Verastem (VSTM) and Akorn (AKRX).

What is SeaSpine's stock symbol?

SeaSpine trades on the NASDAQ under the ticker symbol "SPNE."

Who are SeaSpine's major shareholders?

SeaSpine's stock is owned by many different institutional and retail investors. Top institutional investors include Emerald Advisers LLC (2.13%), Emerald Mutual Fund Advisers Trust (2.12%), Monarch Partners Asset Management LLC (0.31%), Dupont Capital Management Corp (0.10%) and Alliancebernstein L.P. (0.09%). Company insiders that own SeaSpine stock include Beau Standish, John B Henneman III, Keith Valentine, Renee Gaeta and Richard E Caruso.
View institutional ownership trends for SeaSpine

Which major investors are buying SeaSpine stock?

SPNE stock was purchased by a variety of institutional investors in the last quarter, including Emerald Mutual Fund Advisers Trust, Emerald Advisers LLC, Monarch Partners Asset Management LLC, Dupont Capital Management Corp, and Alliancebernstein L.P..
View insider buying and selling activity for SeaSpine
or or view top insider-buying stocks.

How do I buy shares of SeaSpine?

Shares of SPNE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is SeaSpine's stock price today?

One share of SPNE stock can currently be purchased for approximately $19.59.

How much money does SeaSpine make?

SeaSpine has a market capitalization of $649.60 million and generates $154.35 million in revenue each year. The medical equipment provider earns $-43,180,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis.

How many employees does SeaSpine have?

SeaSpine employs 421 workers across the globe.

What is SeaSpine's official website?

The official website for SeaSpine is

Where are SeaSpine's headquarters?

SeaSpine is headquartered at 5770 ARMADA DRIVE, CARLSBAD CA, 92008.

How can I contact SeaSpine?

SeaSpine's mailing address is 5770 ARMADA DRIVE, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-727-8399 or via email at [email protected]

This page was last updated on 8/1/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.